154 results
8-K
EX-99.1
TGTX
TG Therapeutics Inc
1 May 24
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
7:05am
Injection for IV
BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies … to exceed expectations; the risk that our current or future BRIUMVI revenue targets will not be achieved; the failure to obtain and maintain requisite
8-K
EX-99.1
TGTX
TG Therapeutics Inc
28 Feb 24
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
7:24am
(ublituximab-xiiy) 150 mg/6 mL Injection for IV
BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells … that the BRIUMVI launch does not continue to exceed expectations; the risk that our BRIUMVI revenue targets will not be achieved; the failure to obtain
8-K
EX-99.1
TGTX
TG Therapeutics Inc
10 Jan 24
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
7:37am
. BRIUMIVI net product revenue. As we head into 2024, we have our sights set on achieving revenue and expense targets and have built an ambitious plan … February 2024.
2024 Target Guidance
BRIUMVI U.S. net product revenue targets of approximately $41-$46 million and $220-$260 million for the first quarter
8-K
EX-99.1
viqx7p2efdwcc 2bj5p
1 Nov 23
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
7:33am
8-K
e5kze3rlbr
1 Aug 23
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
7:29am
8-K
EX-99.1
w4yq7jix 4105
1 Aug 23
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
7:29am
8-K
EX-99.1
kvflqbt6vypwqpqa2dkt
1 May 23
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
7:35am
8-K
EX-99.1
4dn9kj utat6yu
28 Dec 22
U.S. Commercial launch expected Q1 2023
4:30pm
8-K
EX-99.1
aij2ctefqf3g1b7dwpeu
10 Nov 22
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
7:38am
8-K
EX-99.1
1wq1tcqjexe l2z6k
8 Aug 22
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
7:37am
8-K
EX-10.1
u5wspmt
23 Jun 22
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
EX-99.1
8q2eawc
18 Apr 22
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
7:30am